A status update was recorded on September 3, 2026 for the trial titled "Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial," registered as NCT05411081.
The study is listed as Phase 2 and its current status is active, not recruiting. This means the trial is ongoing but is not currently enrolling new participants.
The trial is evaluating cabozantinib administered with or without atezolizumab in patients with advanced papillary kidney cancer. No results have been reported in this update, and no efficacy or safety conclusions can be drawn from the status change alone.
This entry does not mention substance P directly, and the update reflects only the recruitment and phase status of the PAPMET2 trial as registered on ClinicalTrials.gov. Readers should note that this update is procedural, reflecting trial administration rather than clinical outcomes.
For general background on the compound referenced in this feed, readers can consult the compound overview page for additional context.